Cellular Senescence In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Cellular senescence is a state of irreversible cell-cycle arrest characterized by profound changes in gene expression, chromatin organization, and the secretion of a complex mix of pro-inflammatory factors known as the senescence-associated secretory phenotype (SASP).
Originally described as a tumor-suppressive mechanism, senescence has emerged as a major contributor to [aging] and [neurodegeneration[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/mechanisms.
Senescent cells accumulate in the aging brain and in brains affected by [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--, [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--, [amyotrophic lateral sclerosis[/diseases/[als[/diseases/[als[/diseases/[als--TEMP--/diseases)--FIX--, and [multiple sclerosis[/diseases/[multiple-sclerosis[/diseases/[multiple-sclerosis[/diseases/[multiple-sclerosis--TEMP--/diseases)--FIX--, where they drive chronic neuroinflammation, impair tissue repair, and accelerate disease progression 1() [Link) ([Rueda et al., 2020)) [1].
The therapeutic targeting of senescent cells with senolytic drugs—agents that selectively eliminate senescent cells—represents a promising frontier in the treatment of neurodegenerative diseases, with early clinical trials now underway 3(https://pubmed.ncbi.nlm.nih.gov/38164616/) ([Hu et al., 2024)) [2].
Multiple stressors can induce cellular senescence in the central nervous system (CNS) ([Gonzales et al., 2024)):
- DNA damage: Persistent [DNA damage] from [reactive oxygen species ([ROS[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress--TEMP--/mechanisms)--FIX--, genotoxic stress, or replication errors activates the DNA damage response (DDR), leading to cell-cycle arrest through the p53/p21 and p16INK4a/Rb pathways 4(https://www.sciencedirect.com/science/article/pii/S1568163523003008).
- Telomere shortening: Progressive telomere attrition, particularly in dividing glial cells, triggers replicative senescence 4(https://www.sciencedirect.com/science/article/pii/S1568163523003008).
- Oncogene activation: Aberrant activation of proliferative signaling can paradoxically induce senescence as a protective response.
- Mitochondrial dysfunction: Impaired [mitochondrial dynamics[/entities/[mitochondrial-dynamics[/entities/[mitochondrial-dynamics[/entities/[mitochondrial-dynamics--TEMP--/entities)--FIX-- and increased oxidative stress generate [ROS[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress--TEMP--/mechanisms)--FIX-- that damage DNA, lipids, and proteins, promoting senescence 5(https://link.springer.com/article/10.1007/s12035-025-05504-1).
- Protein aggregation stress: Accumulation of misfolded proteins such as [amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- ], tau], [alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein--TEMP--/proteins)--FIX-- induces proteotoxic stress that triggers senescence 2(https://link.springer.com/article/10.1007/s00204-024-03768-5).
The SASP is the hallmark effector mechanism of senescent cells. Senescent cells secrete a complex cocktail of:
- Pro-inflammatory cytokines: IL-1β, IL-6, IL-8, TNF-α
- Chemokines: CCL2 (MCP-1), CCL3, CCL5, CXCL1, CXCL10
- Matrix metalloproteinases (MMPs): MMP-1, MMP-3, MMP-9
- Growth factors: VEGF, TGF-β, GM-CSF
- Extracellular vesicles and exosomes: Containing inflammatory mediators
The SASP creates a pro-inflammatory microenvironment that can spread senescence to neighboring healthy cells in a paracrine manner—a phenomenon termed the "senescence-bystander effect." In the brain, this paracrine signaling is particularly damaging because it disrupts the delicate cellular interactions between [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--, [astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes--TEMP--/cell-types)--FIX--, [microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia--TEMP--/cell-types)--FIX--/entities/microglia][microglia, and oligodendrocytes that are essential for normal neural function [Link) [Link) ([Sahu et al., 2024)) [3].
Senescence is mediated by two key tumor suppressor pathways:
- p53/p21CIP1 pathway: DNA damage activates ATM/ATR kinases → p53 stabilization → p21 transcription → CDK2 inhibition → Rb hypophosphorylation → cell-cycle arrest [4].
- p16INK4a/Rb pathway: Chronic stress activates p16INK4a → CDK4/6 inhibition → Rb hypophosphorylation → permanent G1 arrest [5].
In the brain, increased expression of p16INK4a and p21 has been detected in [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--, [astrocytes), [microglia/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia--TEMP--/cell-types)--FIX--/entities/microglia, and oligodendrocytes in both aging and neurodegenerative disease [Link) [Link) ([Rajawat et al., 2025)) [6].
[microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia--TEMP--/cell-types)--FIX-- ([Neumann et al., 2025)) [7].
In [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--, senescent [microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia--TEMP--/cell-types)--FIX--" title="[Neumann B, et al. (2025]. Senescent-like [microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia--TEMP--/cell-types)--FIX--/entities/microglia">8.
[astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes--TEMP--/cell-types)--FIX-- undergo senescence in response to oxidative stress and exposure to pathological proteins. Senescent [astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes--TEMP--/cell-types)--FIX-- show:
- Increased SASP factor secretion: Elevated IL-6, interferon-γ, and CCL2 levels.
- Impaired glutamate buffering: Reduced expression of glutamate transporters, leading to excitotoxicity.
- Dysfunctional mitochondria: Elevated [ROS[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress--TEMP--/mechanisms)--FIX-- production activates [NF-κB[/entities/[nf-kb[/entities/[nf-kb[/entities/[nf-kb--TEMP--/entities)--FIX-- signaling.
- Promoted [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- accumulation: SASP-mediated inflammation stimulates amyloidogenic [APP[/genes/[app[/genes/[app[/genes/[app--TEMP--/genes)--FIX-- processing].
- Enhanced tau] pathology: Senescent [astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes--TEMP--/cell-types)--FIX-- promote tau] hyperphosphorylation] and propagation through inflammatory signaling 6(https://www.tandfonline.com/doi/full/10.1080/15384101.2021.1909260).
¶ Oligodendrocyte and OPC Senescence
oligodendrocytes precursor cells (OPCs) can become senescent, with significant consequences:
- Impaired myelination: Senescent OPCs fail to differentiate into mature myelinating oligodendrocytes.
- Suppressed neuronal plasticity: Senescent OPCs suppress neuronal firing and excitatory transmission via CCL3/5-CCR5 signaling 11(https://www.science.org/doi/10.1126/sciadv.adq7665).
- Contribution to white matter degeneration: Oligodendrocyte senescence contributes to age-related white matter loss and myelin degradation.
Although [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- are post-mitotic and do not divide, they can enter a senescence-like state characterized by:
- Increased p21 expression: Despite being non-dividing, [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- upregulate p21 and exhibit DDR activation.
- SASP component secretion: [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- secrete inflammatory mediators that affect surrounding glial cells.
- Altered chromatin structure: Changes in heterochromatin organization and gene expression.
- Lipofuscin accumulation: Build-up of non-degradable lysosomal material 7(https://www.nature.com/articles/s41467-025-66012-3).
In [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--, cellular senescence has been documented across multiple cell types:
- **Senescent [astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes--TEMP--/cell-types)--FIX-- and [microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia--TEMP--/cell-types)--FIX--.
In [ALS[/diseases/[als[/diseases/[als[/diseases/[als--TEMP--/diseases)--FIX--:
- Senescent [astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes--TEMP--/cell-types)--FIX-- contribute to motor neuron death through SASP-mediated toxicity.
- [SOD1/proteins/sod1 mutations promote senescence in spinal cord [astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes--TEMP--/cell-types)--FIX-- and [microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia--TEMP--/cell-types)--FIX--.
- Clearance of senescent glial cells in mouse models restores remyelination capacity.
Senolytics are compounds that selectively eliminate senescent cells by targeting the anti-apoptotic pathways (senescent cell anti-apoptotic pathways, or SCAPs) that allow senescent cells to resist apoptosis:
| Drug |
Mechanism |
Status |
| Dasatinib |
Tyrosine kinase inhibitor; targets SRC family kinases and ephrin receptors |
FDA-approved (cancer); clinical trials for AD |
| Quercetin |
Flavonoid; inhibits BCL-2 family, PI3K, serpines |
Dietary supplement; clinical trials |
| Fisetin |
Flavonoid; inhibits PI3K/AKT/[mTOR[/mechanisms/[mtor-neurodegeneration[/mechanisms/[mtor-neurodegeneration[/mechanisms/[mtor-neurodegeneration--TEMP--/mechanisms)--FIX--, activates AMPK |
Preclinical/early clinical |
| Navitoclax (ABT-263) |
BCL-2/BCL-xL/BCL-w inhibitor |
Clinical trials (cancer); preclinical for neuro |
| ABT-737 |
BCL-2/BCL-xL inhibitor |
Preclinical |
| UBX0101 |
MDM2/p53 interaction inhibitor |
Clinical trials (osteoarthritis) |
Senomorphics suppress the SASP without killing senescent cells:
- Rapamycin: [mTOR[/mechanisms/[mtor-neurodegeneration[/mechanisms/[mtor-neurodegeneration[/mechanisms/[mtor-neurodegeneration--TEMP--/mechanisms)--FIX-- inhibitor; reduces SASP factor translation.
- Metformin: AMPK activator; attenuates [NF-κB[/entities/[nf-kb[/entities/[nf-kb[/entities/[nf-kb--TEMP--/entities)--FIX---driven SASP.
- Ruxolitinib: JAK1/2 inhibitor; blocks SASP cytokine signaling.
The STAMINA (Senolytics To Alleviate Mobility Issues and Neurological Impairments in Ageing) trial is a pioneering 12-week pilot study that administered intermittent doses of dasatinib (100 mg) and quercetin (1250 mg) in 12 older adults aged ≥65 years with slow gait speed and mild cognitive impairment—precursors to [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--.
Participants received the combination for two consecutive days every two weeks.
The study demonstrated feasibility and safety, setting the stage for larger efficacy trials 12()00056-8/fulltext) [9].
Additional clinical efforts include:
- SToMP-AD (Senolytic Therapy to Modulate Progression of Alzheimer's Disease): Testing dasatinib + quercetin in early AD patients.
- Preclinical studies demonstrating that senolytic treatment in tau]-transgenic mice reduces [neurofibrillary tangles[/mechanisms/[neurofibrillary-tangles[/mechanisms/[neurofibrillary-tangles[/mechanisms/[neurofibrillary-tangles--TEMP--/mechanisms)--FIX--, decreases neuroinflammation, and improves memory 3(https://pubmed.ncbi.nlm.nih.gov/38164616/) [Link).
¶ Challenges and Future Directions
- [Blood-Brain Barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier--TEMP--/entities)--FIX-- penetration: Many senolytics have limited CNS bioavailability; nanoparticle delivery systems and focused ultrasound are being explored.
- Cell-type specificity: Current senolytics lack selectivity for specific senescent cell types, raising concerns about off-target effects on healthy cells.
- Biomarker development: Reliable biomarkers of brain senescence (e.g., plasma SASP factors, p16INK4a levels) are needed to monitor treatment efficacy.
- Timing of intervention: Optimal windows for senolytic therapy remain unclear—too early may disrupt beneficial senescence functions; too late may be ineffective.
- Combination approaches: Combining senolytics with [anti-amyloid therapeutics[/mechanisms/[anti-amyloid-therapeutics[/mechanisms/[anti-amyloid-therapeutics[/mechanisms/[anti-amyloid-therapeutics--TEMP--/mechanisms)--FIX-- or [immunotherapy[/treatments/[immunotherapy[/treatments/[immunotherapy[/treatments/[immunotherapy--TEMP--/treatments)--FIX-- may yield synergistic benefits 5().
- [Microglia[/treatments/[immunotherapy[/treatments/[immunotherapy[/treatments/[immunotherapy--TEMP--/treatments)--FIX--
The study of Cellular Senescence In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- [PubMed) - Biomedical literature
- [Alzheimer's Disease Neuroimaging Initiative) - Research data
- [Allen Brain Atlas) - Brain gene expression data
Recent publications position [cellular senescence[/mechanisms/[cellular-senescence[/mechanisms/[cellular-senescence[/mechanisms/[cellular-senescence--TEMP--/mechanisms)--FIX-- as a measurable systems-level process linking molecular aging states to brain structure and glial network dysfunction.
- 2026: [Establishing the relationship between brain cellular senescence and brain structure) (Cell) provides quantitative evidence that senescence-linked molecular programs track with neuroanatomical variation in living human cohorts.[13]
- 2026: [From [Neuron[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX---Centric to Glia-Centric: How Aging Glial Networks Drive Neurodegenerative Disease) (Journal of Neurochemistry) reframes senescence as a networked glial process influencing [microglia[/14][/14][/14]--TEMP--/14]<)--FIX--
- 2026: [neuroinflammation and Cellular Senescence in Brain Aging and Neurodegeneration) (Aging and Disease) summarizes convergent mechanisms linking inflammatory signaling to senescence amplification loops.[15]
Cellular senescence has evolved from being recognized as a tumor-suppressive mechanism to a major contributor to aging and neurodegenerative diseases. The accumulation of senescent cells in the brain, across multiple cell types including [microglia[/entities/[microglia[/entities/[microglia[/entities/[microglia--TEMP--/entities)--FIX--, [astrocytes[/entities/[astrocytes[/entities/[astrocytes[/entities/[astrocytes--TEMP--/entities)--FIX--, oligodendrocytes, and even neurons, creates a pro-inflammatory microenvironment that drives chronic neuroinflammation and accelerates disease progression.
Key therapeutic strategies emerging from this understanding include:
-
Senolytic drugs: Agents like dasatinib plus quercetin that selectively eliminate senescent cells have shown promise in preclinical models and early clinical trials.
-
Senomorphic agents: Drugs that suppress the SASP without killing senescent cells, such as rapamycin and metformin, offer an alternative approach.
-
Targeted delivery: Overcoming the blood-brain barrier remains a key challenge, with nanoparticle delivery systems and focused ultrasound showing promise.
-
Combination therapies: Integrating senolytics with anti-amyloid, anti-[tau[/entities/[tau-protein[/entities/[tau-protein[/entities/[tau-protein--TEMP--/entities)--FIX--, or immunomodulatory therapies may yield synergistic benefits.
The STAMINA trial and other emerging clinical studies are establishing the foundation for senolytics as a novel therapeutic approach to neurodegenerative diseases. As our understanding of the complex biology of senescence continues to grow, so too will the therapeutic options for harnessing this knowledge to treat these devastating disorders.
- [Martínez-Cué C, Rueda N. (2020]. Cellular Senescence in Neurodegenerative Diseases. Frontiers in Cellular Neuroscience, 14, 16. [Link))
- [Gonzales MM, Krishnamurthy S, et al. (2024]. The role of cellular senescence in neurodegenerative diseases. Archives of Toxicology, 98, 2469–2488. [Link))
- [Aguado J, Chaggar HK, Bhatt D, et al. (2024]. Pharmacological targeting of senescence with senolytics as a new therapeutic strategy for neurodegeneration. Molecular Pharmacology, 105(2), 64–74. [Link))
- [Sahu MR, Rani L, Subba R, Mondal AC. (2024]. Cellular senescence in brain aging and neurodegeneration. Ageing Research Reviews, 93, 102141. [Link))
- [Rajawat J, et al. (2025]. Senolytics as modulators of critical signaling pathways: a promising strategy to combat brain aging and neurodegenerative disorders. Molecular Neurobiology. [Link))
- [Bussian TJ, Aziz A, Meyer CF, et al. (2021]. Astrocyte senescence and SASP in neurodegeneration: tau] joins the loop. Cell Cycle, 20(8), 752–764. [Link))
- [Moreno-Blas D, et al. (2025]. Systematic profiling reveals distinct senescence signatures and regulators across human brain cell types. Nature Communications, 16, 66012. [Link))
- [Neumann B, et al. (2025]. Senescent-like [microglia)
- [Hu Y, Fryatt GL, et al. (2024]. Emerging role of senescent [microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia--TEMP--/cell-types)--FIX--/entities/microgliahttps://pmc.ncbi.nlm.nih.gov/articles/PMC10877780/)
- [Si ZZ, et al. (2025]. Senescent brain cell types in [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--: pathological mechanisms and therapeutic opportunities. Ageing Research Reviews, 105, 102711. [Link))
- [Zhang P, et al. (2024]. Impaired macroautophagy in oligodendrocyte precursor cells suppresses neuronal plasticity via a senescence-associated signaling. Science Advances, 10, eadq7665. [Link))
- [Gonzales MM, et al. (2025]. A pilot study of senolytics to improve cognition and mobility in older adults at risk for [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--. eBioMedicine, 103, 105568. [Link)))
- [Murray et al., Establishing the relationship between brain cellular senescence and brain structure (2026))
- [de Majo and Maehlen, From Neuron-Centric to Glia-Centric: How Aging Glial Networks Drive Neurodegenerative Disease (2026))
- [de Majo et al., neuroinflammation and Cellular Senescence in Brain Aging and Neurodegeneration (2026))
🟡 Moderate Confidence
| Dimension |
Score |
| Supporting Studies |
15 references |
| Replication |
33% |
| Effect Sizes |
25% |
| Contradicting Evidence |
33% |
| Mechanistic Completeness |
75% |
Overall Confidence: 55%